

Real-World Evidence Collaborative White Paper Citations Tracker

The Duke-Margolis Center for Health Policy’s Real-World Evidence Collaborative is proud to have its white papers cited in a diverse number of publications. The following running list of citations is current as of December 2022.

Table of Contents

| | |
|--|---------|
| A Framework for Regulatory Use of Real-World Evidence | Page 2 |
| Characterizing RWD Quality and Relevancy for Regulatory Purposes | Page 9 |
| Determining Real-World Data’s Fitness for Use and the Role of Reliability | Page 12 |
| Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility | Page 14 |
| Adding Real-World Evidence to a Totality of Evidence Approach for Evaluating Marketed Product Effectiveness | Page 15 |
| A Roadmap for Developing Study Endpoints in Real-World Settings | Page 17 |
| Point-of-Care Clinical Trials: Integrating Research and Care Delivery | Page 18 |
| Aligning Shared Evidentiary Needs Among Payers and Regulators for a Real-World Data Ecosystem | Page 18 |

A Framework for Regulatory Use of Real-World Evidence

“The First White Paper”

- Armağan, B., Kılıç, L., Önen, F., & Kiraz, S. (2020). Real-life parameters in rheumatology. *Ulusal Romatoloji Dergisi*, 12(Special Issue), 73–80. <https://doi.org/10.4274/raed.galenos.2020.S110>
- Arondekar, B., Duh, M. S., Bhak, R. H., DerSarkissian, M., Huynh, L., Wang, K., Wojciehowski, J., Wu, M., Wornson, B., Niyazov, A., & Demetri, G. D. (2022). Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020. *Clinical Cancer Research*, 28(1), 27–35. <https://doi.org/10.1158/1078-0432.CCR-21-2639>
- A.S. Kolbin & D. Yu. Belousov. (2022). Chinese experience on using RWE to support drug research, development and evaluation. *Real-World Data & Evidence*, 1(2), 17–27.
- Baumfeld Andre, E., Reynolds, R., Caubel, P., Azoulay, L., & Dreyer, N. A. (2020). Trial designs using real-world data: The changing landscape of the regulatory approval process. *Pharmacoepidemiology and Drug Safety*, 29(10), 1201–1212. <https://doi.org/10.1002/pds.4932>
- Berkan Armağan, Levent Kilic, Fatos Onen, & Sedat Kiraz. (2020). Real-life parameters in rheumatology. *Journal of Turkish Society for Rheumatology*, 12, 73–80.
- Bettina Schneider, Petra Maria Asprion, & Frank Grimberg. (2019). Human-centered Artificial Intelligence: A Multidimensional Approach towards Real World Evidence. In *Proceedings of the 21st International Conference on Enterprise Information Systems* (pp. 381–390). Science and Technology Publications.
- Brown, J. P., Douglas, I. J., Hanif, S., Thwaites, R. M. A., & Bate, A. (2021). Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact. *Value in Health*, 24(9), 1241–1244. <https://doi.org/10.1016/j.jval.2021.03.020>
- Bruxvoort, K., Sy, L. S., Luo, Y., & Tseng, H. F. (2018). Real-World Evidence for Regulatory Decisions: Concomitant Administration of Zoster Vaccine Live and Pneumococcal Polysaccharide Vaccine. *American Journal of Epidemiology*, 187(9), 1856–1862. <https://doi.org/10.1093/aje/kwy076>
- Burcu, M., Dreyer, N. A., Franklin, J. M., Blum, M. D., Critchlow, C. W., Perfetto, E. M., & Zhou, W. (2020). Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms. *Pharmacoepidemiology and Drug Safety*, 29(10), 1228–1235. <https://doi.org/10.1002/pds.4975>
- Caleigh Propes, Sarah Sheehan, & Rachele Hendricks-Sturup. (2022). *Point-of-Care Clinical Trials: Integrating Research and Care Delivery*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/point-care-clinical-trials-integrating-research-and-care-delivery>
- Christian, J. B., Brouwer, E. S., Girman, C. J., Bennett, D., Davis, K. J., & Dreyer, N. A. (2020).

- Masking in Pragmatic Trials: Who, What, and When to Blind. *Therapeutic Innovation & Regulatory Science*, 5(2), 431–436. <https://doi.org/10.1007/s43441-019-00073-7>
- Daphne Guinn, Subha Madhavan, & Robert A. Beckman. (2018). Harnessing Real-World Data to Inform Platform Trial Design. In *Platform Trial Designs in Drug Development* (First).
- Daubner-Bendes, R., Kovács, S., Niewada, M., Huic, M., Drummond, M., Ciani, O., Blankart, C. R., Mandrik, O., Torbica, A., Yfantopoulos, J., Petrova, G., Holownia-Voloskova, M., Taylor, R. S., Al, M., Piniashko, O., Lorenzovici, L., Tarricone, R., Zemplényi, A., & Kaló, Z. (2021). Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. *Frontiers in Public Health*, 8. <https://www.frontiersin.org/articles/10.3389/fpubh.2020.612410>
- De, S., Larson, L., Kelly, K., Hanson, B., & Mack, C. D. (2021). Leveraging Real-World Evidence: A Paradigm Shift in Regulation. *Journal of Orthopaedic Trauma*, 35, S13. <https://doi.org/10.1097/BOT.0000000000002039>
- Dreyer, N. A. (2018). Advancing a Framework for Regulatory Use of Real-World Evidence: When Real Is Reliable. *Therapeutic Innovation & Regulatory Science*, 5(3), 362–368. <https://doi.org/10.1177/2168479018763591>
- Dron, L., Golchi, S., Hsu, G., & Thorlund, K. (2019). Minimizing control group allocation in randomized trials using dynamic borrowing of external control data – An application to second line therapy for non-small cell lung cancer. *Contemporary Clinical Trials Communications*, 16, 100446. <https://doi.org/10.1016/j.conctc.2019.100446>
- Enogela, E. M., Buchanan, T., Carter, C. S., Elk, R., Gazaway, S. B., Goodin, B. R., Jackson, E. A., Jones, R., Kennedy, R. E., Perez-Costas, E., Zubkoff, L., Zumbro, E. L., Markland, A. D., & Buford, T. W. (2022). Preserving independence among under-resourced older adults in the Southeastern United States: Existing barriers and potential strategies for research. *International Journal for Equity in Health*, 21(1), 119. <https://doi.org/10.1186/s12939-022-01721-5>
- Erin Hammers Forstg, Benjamin Kahn, Amanda Wagner Gee, & Carolyn Shore. (2019). *Examining the Impact of Real-World Evidence on Medical Product Development: Proceedings of a Workshop Series*. The National Academies Press. <https://nap.nationalacademies.org/catalog/25352/examining-the-impact-of-real-world-evidence-on-medical-product-development>
- Girman, C. J., Ritchey, M. E., Zhou, W., & Dreyer, N. A. (2019). Considerations in characterizing real-world data relevance and quality for regulatory purposes: A commentary. *Pharmacoepidemiology and Drug Safety*, 28(4), 439–442. <https://doi.org/10.1002/pds.4697>
- Gliklich, R. E., & Leavy, M. B. (2020). Assessing Real-World Data Quality: The Application of Patient Registry Quality Criteria to Real-World Data and Real-World Evidence. *Therapeutic Innovation & Regulatory Science*, 5(2), 303–307. <https://doi.org/10.1007/s43441-019-00058-6>

- Grabner, M., Molife, C., Wang, L., Winfree, K. B., Cui, Z. L., Carter, G. C., & Hess, L. M. (2021). Data Integration to Improve Real-world Health Outcomes Research for Non-Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration. *JMIR Cancer*, 7(2), e23161. <https://doi.org/10.2196/23161>
- Gregory Daniel, Christina Silcox, Jonathan Bryan, Mark McClellan, Morgan Romine, & Katherine Frank. (2018). *Characterizing RWD Quality and Relevancy for Regulatory Purposes*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/characterizing-rwd-quality-and-relevancy-regulatory-purposes-0>
- Guinn, D., Wilhelm, E. E., Lieberman, G., & Khozin, S. (2019). Assessing function of electronic health records for real-world data generation. *BMJ Evidence-Based Medicine*, 24(3), 95–98. <https://doi.org/10.1136/bmjebm-2018-111111>
- Hi Gin Sung, Han-Heui Park, Gyu-Won Jung, & Ju-Young Shin. (2020). Current Status and Examples of US FDA or EMA's Regulatory Decision using Real World Data/Real World Evidence. *Yakhak Hoeji*, 64(2).
- ISPOR 2022-2023 Top 10 HEOR Trends Report*. (2022). ISPOR. <https://www.ispor.org/heor-resources/about-heor/top-10-heor-trends>
- Jaksa, A., Wu, J., Jónsson, P., Eichler, H.-G., Vititoe, S., & Gatto, N. M. (2021). Organized structure of real-world evidence best practices: Moving from fragmented recommendations to comprehensive guidance. *Journal of Comparative Effectiveness Research*, 10(9), 711–731. <https://doi.org/10.2217/cer-2020-0228>
- Ji-Hwan Bae, Han-Heui Park, Gyu-Won Jung, Hi Gin Sung, Jiyoung Yang, JungEun Hwang, Dongwon Yoon, Yunha Noh, & Ju-Young Shin. (2019). Establishment of Framework for the Development and Review of Drugs Based on Real-World Data/Real-World Evidence. *약물역학위해관리학회지*, 11, 62–71.
- Jiyeon Kang. (2022). Real-World Data in Health Technology Assessment: Do We Know It Well Enough? In *Precision Oncology and Cancer Biomarkers* (Vol. 5). Springer.
- Jormanainen, V. (2019). Valtakunnallisten Kanta-palvelujen käyttöönotto apteekeissa ja kuntien julkisessa perusterveydenhuollossa vuosina 2010–2016. *Finnish Journal of eHealth and eWelfare*, 11(3), Article 3. <https://doi.org/10.23996/fjhw.77601>
- Katkade, V. B., Sanders, K. N., & Zou, K. H. (2018). Real world data: An opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. *Journal of Multidisciplinary Healthcare*, 11, 295–304. <https://doi.org/10.2147/JMDH.S160029>
- Kerra Mercon, Nirosha Mahendraratnam, Joy Eckert, Christina Silcox, Morgan Romine, Kathryn Lallinger, Adam Kroetsch, Huzyfa Fazili, Marta Wosinska, & Mark McClellan. (2020). *A Roadmap for Developing Study Endpoints in Real-World Settings*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/roadmap-developing-study-endpoints-real-world-settings>

- Khosla, S., White, R., Medina, J., Ouwens, M., Emmas, C., Koder, T., Male, G., & Leonard, S. (2018). Real world evidence (RWE) – a disruptive innovation or the quiet evolution of medical evidence generation? *F1000Research*, 7, 111. <https://doi.org/10.12688/f1000research.13585.2>
- Klonoff, D. C. (2020). The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics. *Journal of Diabetes Science and Technology*, 14(2), 345–349. <https://doi.org/10.1177/1932296819832661>
- Kraus, V. B., Simon, L. S., Katz, J. N., Neogi, T., Hunter, D., Guermazi, A., & Karsdal, M. A. (2019). Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA’s accelerated approval regulations for disease modifying osteoarthritis drugs. *Osteoarthritis and Cartilage*, 27(4), 571–579. <https://doi.org/10.1016/j.joca.2018.11.002>
- Kugener, V. F., Freedland, E. S., Maynard, K. I., Aimer, O., Webster, P. S., Salas, M., & Gossell-Williams, M. (2021). Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities. *Drug Safety*, 44(8), 843–852. <https://doi.org/10.1007/s40264-021-01078-8>
- Li, W., Fan, H., Tang, J., Wang, Q., Zhang, X., & El-Awady, J. A. (2019). Effects of alloying on deformation twinning in high entropy alloys. *Materials Science and Engineering: A*, 763, 138143. <https://doi.org/10.1016/j.msea.2019.138143>
- Lim, R., Lee, D. K., Sabourin, P., Ferguson, J., Metcalf, M., Smith, M., Corriol-Rohou, S., Eichler, H.-G., Lumpkin, M., Hirsch, G., Chen, I. M., O’Rourke, B., Schiel, A., Crabb, N., Aronson, N., Pezalla, E., Boutin, M., Binder, L., & Wilhelm, L. (2019). Recognizing that Evidence is Made, not Born. *Clinical Pharmacology & Therapeutics*, 105(4), 844–856. <https://doi.org/10.1002/cpt.1317>
- Lin, X., Li, G., & Quan, H. (2022). Strategy for Combining Information from Real World Data Sources When Individual Patient Data Are Not Simultaneously Accessible. *Statistics in Biopharmaceutical Research*, 14(4), 456–462. <https://doi.org/10.1080/19466315.2022.2063170>
- Lydia Wenxin Lin, Jeonghoon Ahn, Diana Beatriz S. Bayani, Kelvin Chan, Dechen Choiphel, Wandrudee Isaranuwatjai, Sarin KC, Brendon Kearney, Jing Lou, Ryota Nakamura, Fiona Pearce, Shankar Prinja, Raoh-Fang PWU, Asrul Akmal Shafie, Yot Teerawattananon, Sean Tunis, Hui-Min Wu, John Zalcborg, & Hwee-Lin Wee. (2020). *Use of Real-World Data and Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia*. REALISE Group. https://hiper.nus.edu.sg/wp-content/uploads/2021/03/REALISE-Full-guidance-post-feedback_20201211-version-1.1.pdf
- Marc Berger, Greg Daniel, Katherine Frank, Adrian Hernandez, Mark McClellan, Sally Okun, Marc Overhage, Richard Platt, Morgan Romine, Sean Tunis, & Marcus Wilson. (2017). *A Framework for Regulatory Use of Real-World Evidence*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/framework-regulatory-use->

real-world-evidence

- Mofid, S., Bolislis, W. R., & Kühler, T. C. (2022). Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA. *Clinical Therapeutics*, 44(2), 306–322. <https://doi.org/10.1016/j.clinthera.2021.12.010>
- Neil A Belson. (2020). Emergence of Real World Evidence in Precision Medicine. In *The Road from Nanomedicine to Precision Medicine* (First). Jenny Stanford Publishing.
- Nicole Rodrigues. (2019). Real World Evidence: Impact on Clinical Data. *Data Basics*, 25(1). <https://scdm.org/wp-content/uploads/2019/12/1.pdf#page=18>
- Nirosha Mahendraratnam, Christina Silcox, Kerra Mercon, Adam Kroetsch, Morgan Romine, Nicholas Harisson, Adam Aten, Rachel Sherman, Gregory Daniel, & Mark McClellan. (2019). *Determining Real-World Data's Fitness for Use and the Role of Reliability*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/determining-real-world-datas-fitness-use-and-role-reliability>
- Nirosha Mahendraratnam, Joy Eckert, Kerra Mercon, Katherine Frank, Morgan Romine, Adam Kroetsch, Rachel Sherman, Gregory Daniel, & Mark McClellan. (2019). *Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/understanding-need-non-interventional-studies-using-secondary-data-generate-real-world>
- Nirosha Mahendraratnam, Kerra Mercon, Joy Eckert, Morgan Romine, Adam Kroetsch, Katherine Frank, Rachel Sherman, Gregory Daniel, & Mark McClellan. (2019). *Adding Real-World Evidence to a Totality of Evidence Approach for Evaluating Marketed Product Effectiveness*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/adding-real-world-evidence-totality-evidence-approach-evaluating-marketed-product>
- Oksen, D., Prince, P., Boutmy, E., Garry, E. M., Ellers-Lenz, B., Estrin, A., Johne, A., Verpillat, P., & Gatto, N. M. (2022). Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort study. *Clinical and Translational Science*, 15(8), 1990–1998. <https://doi.org/10.1111/cts.13315>
- O'Leary, C. P., & Cavender, M. A. (2020). Emerging opportunities to harness real world data: An introduction to data sources, concepts, and applications. *Diabetes, Obesity and Metabolism*, 22(S3), 3–12. <https://doi.org/10.1111/dom.13948>
- Raman, S. R., O'Brien, E. C., Hammill, B. G., Nelson, A. J., Fish, L. J., Curtis, L. H., & Marsolo, K. (2022). Evaluating fitness-for-use of electronic health records in pragmatic clinical trials: Reported practices and recommendations. *Journal of the American Medical Informatics Association*, 29(5), 798–804. <https://doi.org/10.1093/jamia/ocac004>
- Rebecca Ray, Trevan Locke, & Rachele Hendricks-Sturup. (2022). *Aligning Shared Evidentiary Needs Among Payers and Regulators for a Real-World Data Ecosystem*.

- Duke-Margolis Center for Health Policy.
<https://healthpolicy.duke.edu/publications/aligning-shared-evidentiary-needs-among-payers-and-regulators-real-world-data>
- Roberts, M. H., & Ferguson, G. T. (2021). Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions. *PharmacoEconomics - Open*, 5(1), 3–11.
<https://doi.org/10.1007/s41669-020-00221-y>
- Rosenberg, M., Sheehan, S., Zhou, E., Pinnow, E., Burnell, J., Romine, M., & Dal Pan, G. (2020). FDA postmarketing safety labeling changes: What have we learned since 2010 about impacts on prescribing rates, drug utilization, and treatment outcomes. *Pharmacoepidemiology and Drug Safety*, 29(9), 1022–1029.
<https://doi.org/10.1002/pds.5073>
- Rudrapatna, V. A., & Butte, A. J. (2020). Opportunities and challenges in using real-world data for health care. *The Journal of Clinical Investigation*, 130(2), 565–574.
<https://doi.org/10.1172/JCI129197>
- Samson, S. I., Konty, K., Lee, W.-N., Quisel, T., Foschini, L., Kerr, D., Liska, J., Mills, H., Hollingsworth, R., Greenberg, M., & Beal, A. C. (2021). Quantifying the Impact of Influenza Among Persons With Type 2 Diabetes Mellitus: A New Approach to Determine Medical and Physical Activity Impact. *Journal of Diabetes Science and Technology*, 15(1), 44–52. <https://doi.org/10.1177/1932296819883340>
- Sarri, G., Patorno, E., Yuan, H., Guo, J. (Jeff), Bennett, D., Wen, X., Zullo, A. R., Largent, J., Panaccio, M., Gokhale, M., Moga, D. C., Ali, M. S., & Debray, T. P. A. (2022). Framework for the synthesis of non-randomised studies and randomised controlled trials: A guidance on conducting a systematic review and meta-analysis for healthcare decision making. *BMJ Evidence-Based Medicine*, 27(2), 109–119.
<https://doi.org/10.1136/bmjebm-2020-111493>
- Stewart, M., Norden, A. D., Dreyer, N., Henk, H. J., Abernethy, A. P., Chrischilles, E., Kushi, L., Mansfield, A. S., Khozin, S., Sharon, E., Arunajadai, S., Carnahan, R., Christian, J. B., Miksad, R. A., Sakoda, L. C., Torres, A. Z., Valice, E., & Allen, J. (2019). An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer. *JCO Clinical Cancer Informatics*, 3, 1–15. <https://doi.org/10.1200/CCI.18.00155>
- Sung, H. G., Park, H.-H., Jung, G.-W., & Shin, J.-Y. (2020). Current Status and Examples of US FDA or EMA's Regulatory Decision using Real World Data/Real World Evidence. *Yakhak Hoeji*, 64(2), 136–155. <https://doi.org/10.17480/psk.2020.64.2.136>
- Tan, G. S. Q., Sloan, E. K., Lambert, P., Kirkpatrick, C. M. J., & Ilomäki, J. (2023). Drug repurposing using real-world data. *Drug Discovery Today*, 28(1), 103422.
<https://doi.org/10.1016/j.drudis.2022.103422>
- Villines, T. C., Cziraky, M. J., & Amin, A. N. (2020). Awareness, Knowledge, and Utility of RCT Data vs RWE: Results From a Survey of US Cardiologists: Real-world Evidence in Clinical Decision Making. *Clinical Medicine Insights: Cardiology*, 14,

1179546820953410. <https://doi.org/10.1177/1179546820953410>
- Wang, S. V., Sreedhara, S. K., & Schneeweiss, S. (2022). Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions. *Nature Communications*, 13(1), Article 1. <https://doi.org/10.1038/s41467-022-32310-3>
- Webster, J., & Smith, B. D. (2019). The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia. *Clinical Therapeutics*, 41(2), 336–349. <https://doi.org/10.1016/j.clinthera.2018.12.013>
- Weng, X. (2018). Real-world evidence approach to traditional herbal medicinal products. *Drug Discovery Today*, 23(7), 1321–1323. <https://doi.org/10.1016/j.drudis.2018.05.008>
- Zhu, M., Sridhar, S., Hollingsworth, R., Chit, A., Kimball, T., Murmello, K., Greenberg, M., Gurunathan, S., & Chen, J. (2020). Hybrid clinical trials to generate real-world evidence: Design considerations from a sponsor's perspective. *Contemporary Clinical Trials*, 94, 105856. <https://doi.org/10.1016/j.cct.2019.105856>
- Сергеевич, К. А., & Юрьевич, Б. Д. (2022). КИТАЙСКИЙ ОПЫТ ПО ИСПОЛЬЗОВАНИЮ ДОКАЗАТЕЛЬСТВ, ПОЛУЧЕННЫХ НА ОСНОВЕ ДАННЫХ РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКИ В ПРОЦЕССЕ РАЗРАБОТКИ, ИССЛЕДОВАНИЯ И ОЦЕНКИ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ. *Реальная клиническая практика: данные и доказательства*, 2(1), Article 1.

Characterizing RWD Quality and Relevancy for Regulatory Purposes

“The Data Quality Paper”

- Alobaida, M., Alrumayh, A., Oguntade, A. S., Al-Amodi, F., & Bwalya, M. (2021). Cardiovascular Safety and Superiority of Anti-Obesity Medications. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, 14, 3199–3208. <https://doi.org/10.2147/DMSO.S311359>
- Beyrer, J., Abedtash, H., Hornbuckle, K., & Murray, J. F. (2022). A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms. *Journal of Comparative Effectiveness Research*, 11(7), 499–511. <https://doi.org/10.2217/ce-2022-0006>
- Brown, J. P., Douglas, I. J., Hanif, S., Thwaites, R. M. A., & Bate, A. (2021). Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact. *Value in Health*, 24(9), 1241–1244. <https://doi.org/10.1016/j.jval.2021.03.020>
- Burcu, M., Dreyer, N. A., Franklin, J. M., Blum, M. D., Critchlow, C. W., Perfetto, E. M., & Zhou, W. (2020). Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms. *Pharmacoepidemiology and Drug Safety*, 29(10), 1228–1235. <https://doi.org/10.1002/pds.4975>
- Dreyer, N. A., Mack, C. D., Anderson, R. B., Wojtys, E. M., Hershman, E. B., & Sills, A. (2019). Lessons on Data Collection and Curation From the NFL Injury Surveillance Program. *Sports Health*, 11(5), 440–445. <https://doi.org/10.1177/1941738119854759>
- Franklin, J. M., Glynn, R. J., Martin, D., & Schneeweiss, S. (2019). Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making. *Clinical Pharmacology & Therapeutics*, 105(4), 867–877. <https://doi.org/10.1002/cpt.1351>
- Gregory Daniel, Christina Silcox, Jonathan Bryan, Mark McClellan, Morgan Romine, & Katherine Frank. (2018). *Characterizing RWD Quality and Relevancy for Regulatory Purposes*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/characterizing-rwd-quality-and-relevancy-regulatory-purposes-0>
- Gressler, L. E. (2021). *The Creation of Objective Performance Criteria and Generation of Predictive Models among Medical Devices in a Vascular Space* [Ph.D., University of Maryland, Baltimore]. <https://www.proquest.com/docview/2537953650/abstract/5983EFA19019497EPQ/1>
- Gressler, L. E., Link to external site, this link will open in a new window, Marinac-Dabic, D., dosReis, S., Goodney, P., Link to external site, this link will open in a new window, Mullins, C. D., & Shaya, F. (2022). Creation of objective performance criteria among medical devices. *BMJ Surgery, Interventions, & Health Technologies*, 4(1), e000106. <https://doi.org/10.1136/bmjst-2021-000106>
- Hanson, G., Chitnis, T., Williams, M. J., Gan, R. W., Julian, L., Mace, K., Chia, J., Wormser, D.,

- Martinec, M., Astorino, T., Leviner, N., Maung, P., Jan, A., & Belendiuk, K. (2022). Generating real-world data from health records: Design of a patient-centric study in multiple sclerosis using a commercial health records platform. *JAMIA Open*, 5(1), ooab110. <https://doi.org/10.1093/jamiaopen/ooab110>
- He, W., Fang, Y., Wang, H., & Chan, I. (2021). Applying Quantitative Approaches in the Use of RWE in Clinical Development and Life-Cycle Management. *Statistics in Biopharmaceutical Research*, 0(0), 1–12. <https://doi.org/10.1080/19466315.2021.1927827>
- Jennifer R. Popovic. (2019). *Real-world data as real-world evidence: Establishing the meaning of data as a prerequisite to determining secondary-use value*. PharaSUG2019. <https://www.lexjansen.com/pharmasug/2019/RW/PharmaSUG-2019-RW-310.pdf>
- Kugener, V. F., Freedland, E. S., Maynard, K. I., Aimer, O., Webster, P. S., Salas, M., & Gossell-Williams, M. (2021). Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities. *Drug Safety*, 44(8), 843–852. <https://doi.org/10.1007/s40264-021-01078-8>
- Levenson, M., He, W., Chen, L., Dharmarajan, S., Izem, R., Meng, Z., Pang, H., & Rockhold, F. (2022). Statistical Consideration for Fit-for-Use Real-World Data to Support Regulatory Decision Making in Drug Development. *Statistics in Biopharmaceutical Research*, 0(0), 1–8. <https://doi.org/10.1080/19466315.2022.2120533>
- Okun, S. (2019). The Missing Reality of Real Life in Real-World Evidence. *Clinical Pharmacology & Therapeutics*, 106(1), 136–138. <https://doi.org/10.1002/cpt.1465>
- O’Leary, C. P., & Cavender, M. A. (2020). Emerging opportunities to harness real world data: An introduction to data sources, concepts, and applications. *Diabetes, Obesity and Metabolism*, 22(S3), 3–12. <https://doi.org/10.1111/dom.13948>
- O’Neill, T., Miksad, R., Miller, D., Maloney, L., John, A., Hiller, C., & Hornberger, J. (2019). ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products. *Value in Health*, 22(7), 754–761. <https://doi.org/10.1016/j.jval.2019.03.020>
- Raman, S. R., O’Brien, E. C., Hammill, B. G., Nelson, A. J., Fish, L. J., Curtis, L. H., & Marsolo, K. (2022). Evaluating fitness-for-use of electronic health records in pragmatic clinical trials: Reported practices and recommendations. *Journal of the American Medical Informatics Association*, 29(5), 798–804. <https://doi.org/10.1093/jamia/ocac004>
- Rivera, D. R., Henk, H. J., Garrett-Mayer, E., Christian, J. B., Belli, A. J., Bruinooge, S. S., Espirito, J. L., Sweetnam, C., Izano, M. A., Natanzon, Y., Robert, N. J., Walker, M. S., Cohen, A. B., Boyd, M., Enewold, L., Hansen, E., Honnold, R., Kushi, L., Mishra Kalyani, P. S., ... Allen, J. D. (2022). The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies. *Clinical Pharmacology & Therapeutics*, 111(1), 283–292. <https://doi.org/10.1002/cpt.2453>
- Wang, S. V., & Schneeweiss, S. (2022). A Framework for Visualizing Study Designs and Data

Observability in Electronic Health Record Data. *Clinical Epidemiology*, 14, 601–608.
<https://doi.org/10.2147/CLEP.S358583>

Determining Real-World Data's Fitness for Use and the Role of Reliability

"The Data Reliability Paper"

- Beyrer, J., Abedtash, H., Hornbuckle, K., & Murray, J. F. (2022). A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms. *Journal of Comparative Effectiveness Research*, 11(7), 499–511. <https://doi.org/10.2217/cer-2022-0006>
- Boikos, C., Imran, M., De Lusignan, S., Ortiz, J. R., Patriarca, P. A., & Mansi, J. A. (2022). Integrating Electronic Medical Records and Claims Data for Influenza Vaccine Research. *Vaccines*, 10(5), Article 5. <https://doi.org/10.3390/vaccines10050727>
- Boyle, J. M., Hegarty, G., Frampton, C., Harvey-Jones, E., Dodkins, J., Beyer, K., George, G., Sullivan, R., Booth, C., & Aggarwal, A. (2021). Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study. *European Journal of Cancer*, 155, 136–144. <https://doi.org/10.1016/j.ejca.2021.07.001>
- Cocoros, N. M., Arlett, P., Dreyer, N. A., Ishiguro, C., Iyasu, S., Sturkenboom, M., Zhou, W., & Toh, S. (2021). The Certainty Framework for Assessing Real-World Data in Studies of Medical Product Safety and Effectiveness. *Clinical Pharmacology & Therapeutics*, 109(5), 1189–1196. <https://doi.org/10.1002/cpt.2045>
- Csoke, E., Landes, S., Francis, M. J., Ma, L., Teotico Pohlhaus, D., & Anquez-Traxler, C. (2022). How can real-world evidence aid decision making during the life cycle of nonprescription medicines? *Clinical and Translational Science*, 15(1), 43–54. <https://doi.org/10.1111/cts.13129>
- Daubner-Bendes, R., Kovács, S., Niewada, M., Huic, M., Drummond, M., Ciani, O., Blankart, C. R., Mandrik, O., Torbica, A., Yfantopoulos, J., Petrova, G., Holownia-Voloskova, M., Taylor, R. S., Al, M., Piniashko, O., Lorenzovici, L., Tarricone, R., Zemplényi, A., & Kaló, Z. (2021). Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. *Frontiers in Public Health*, 8. <https://www.frontiersin.org/articles/10.3389/fpubh.2020.612410>
- Jaksa, A., Wu, J., Jónsson, P., Eichler, H.-G., Vititoe, S., & Gatto, N. M. (2021). Organized structure of real-world evidence best practices: Moving from fragmented recommendations to comprehensive guidance. *Journal of Comparative Effectiveness Research*, 10(9), 711–731. <https://doi.org/10.2217/cer-2020-0228>
- Lentz, T. A., Curtis, L. H., Rockhold, F. W., Martin, D., Andersson, T. L. G., Arias, C., Berlin, J. A., Binns, C., Cook, A., Cziraky, M., Dent, R., Desai, M., Emmett, A., Esserman, D., George, J., Hantel, S., Heagerty, P., Hernandez, A. F., Hucko, T., ... Ellenberg, S. S. (2020). Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting. *Therapeutic Innovation & Regulatory Science*, 5(6), 1477–1488.

- <https://doi.org/10.1007/s43441-020-00175-7>
- Lydia Wenxin Lin, Jeonghoon Ahn, Diana Beatriz S. Bayani, Kelvin Chan, Dechen Choiphel, Wandrudee Isaranuwachai, Sarin KC, Brendon Kearney, Jing Lou, Ryota Nakamura, Fiona Pearce, Shankar Prinja, Raoh-Fang PWU, Asrul Akmal Shafie, Yot Teerawattananon, Sean Tunis, Hui-Min Wu, John Zalcberg, & Hwee-Lin Wee. (2020). *Use of Real-World Data and Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia*. REALISE Group. https://hiper.nus.edu.sg/wp-content/uploads/2021/03/REALISE-Full-guidance-post-feedback_20201211-version-1.1.pdf
- Nirosha Mahendraratnam, Christina Silcox, Kerra Mercon, Adam Kroetsch, Morgan Romine, Nicholas Harisson, Adam Aten, Rachel Sherman, Gregory Daniel, & Mark McClellan. (2019). *Determining Real-World Data's Fitness for Use and the Role of Reliability*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/determining-real-world-datas-fitness-use-and-role-reliability>
- O'Leary, C. P., & Cavender, M. A. (2020). Emerging opportunities to harness real world data: An introduction to data sources, concepts, and applications. *Diabetes, Obesity and Metabolism*, 22(S3), 3–12. <https://doi.org/10.1111/dom.13948>
- Raman, S. R., O'Brien, E. C., Hammill, B. G., Nelson, A. J., Fish, L. J., Curtis, L. H., & Marsolo, K. (2022). Evaluating fitness-for-use of electronic health records in pragmatic clinical trials: Reported practices and recommendations. *Journal of the American Medical Informatics Association*, 29(5), 798–804. <https://doi.org/10.1093/jamia/ocac004>
- Rivera, D. R., Henk, H. J., Garrett-Mayer, E., Christian, J. B., Belli, A. J., Bruinooge, S. S., Espirito, J. L., Sweetnam, C., Izano, M. A., Natanzon, Y., Robert, N. J., Walker, M. S., Cohen, A. B., Boyd, M., Enewold, L., Hansen, E., Honnold, R., Kushi, L., Mishra Kalyani, P. S., ... Allen, J. D. (2022). The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies. *Clinical Pharmacology & Therapeutics*, 111(1), 283–292. <https://doi.org/10.1002/cpt.2453>

Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility

“The Credibility Paper”

- Beyrer, J., Abedtash, H., Hornbuckle, K., & Murray, J. F. (2022). A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms. *Journal of Comparative Effectiveness Research*, 11(7), 499–511. <https://doi.org/10.2217/cer-2022-0006>
- Dreyer, N. A., Hall, M., & Christian, J. B. (2020). Modernizing Regulatory Evidence with Trials and Real-World Studies. *Therapeutic Innovation & Regulatory Science*, 5(5), 1112–1115. <https://doi.org/10.1007/s43441-020-00131-5>
- Franklin, J. M., Liaw, K.-L., Iyasu, S., Critchlow, C. W., & Dreyer, N. A. (2021). Real-world evidence to support regulatory decision making: New or expanded medical product indications. *Pharmacoepidemiology and Drug Safety*, 30(6), 685–693. <https://doi.org/10.1002/pds.5222>
- Mack, C. D., Pavesio, A., Kelly, K., Irwin, D. E., Maislin, G., Jones, J., Wester, T., & Zura, R. (2021). Breaking Barriers: Studying Fracture Healing in the BONES Program. *Journal of Orthopaedic Trauma*, 35, S22. <https://doi.org/10.1097/BOT.0000000000002035>
- Nirosha Mahendraratnam, Joy Eckert, Kerra Mercon, Katherine Frank, Morgan Romine, Adam Kroetsch, Rachel Sherman, Gregory Daniel, & Mark McClellan. (2019). *Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/understanding-need-non-interventional-studies-using-secondary-data-generate-real-world>
- O'Donnell, J. C., Le, T. K., Dobrin, R., Higashi, M., Pereira, A., Wagner, S., Yang, A., & Hukkelhoven, M. (2021). Evolving use of real-world evidence in the regulatory process: A focus on immuno-oncology treatment and outcomes. *Future Oncology*, 17(3), 333–347. <https://doi.org/10.2217/fon-2020-0591>
- Sheffield, K. M., Dreyer, N. A., Murray, J. F., Faries, D. E., & Klopchin, M. N. (2020). Replication of randomized clinical trial results using real-world data: Paving the way for effectiveness decisions. *Journal of Comparative Effectiveness Research*, 9(15), 1043–1050. <https://doi.org/10.2217/cer-2020-0161>
- Wherry, K., Stromberg, K., Hinnenthal, J. A., Wallenfelsz, L. A., El-Chami, M. F., & Bockstedt, L. (2020). Using Medicare Claims to Identify Acute Clinical Events Following Implantation of Leadless Pacemakers. *Pragmatic and Observational Research*, 11, 19–26. <https://doi.org/10.2147/POR.S240913>

Adding Real-World Evidence to a Totality of Evidence Approach for Evaluating Marketed Product Effectiveness

“The Totality of Evidence Paper”

- Beena Bhuiyan Khan. (2021). *View Public Comments for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (CAG-00460N)*.
- Boikos, C., Imran, M., De Lusignan, S., Ortiz, J. R., Patriarca, P. A., & Mansi, J. A. (2022). Integrating Electronic Medical Records and Claims Data for Influenza Vaccine Research. *Vaccines*, 10(5), Article 5. <https://doi.org/10.3390/vaccines10050727>
- Boikos, C., McGovern, I., Molrine, D., Ortiz, J. R., Puig-Barberà, J., & Haag, M. (2022). Review of Analyses Estimating Relative Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Three Consecutive US Influenza Seasons. *Vaccines*, 10(6), Article 6. <https://doi.org/10.3390/vaccines10060896>
- Boikos, C., McGovern, I., Ortiz, J. R., Puig-Barberà, J., Versage, E., & Haag, M. (2022). Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States. *Vaccines*, 10(9), Article 9. <https://doi.org/10.3390/vaccines10091456>
- Contemporary Applications of Real-World Evidence in Regulatory Decision Making: A Case Series Review – Medical Affairs Professional Society*. (n.d.). Retrieved December 8, 2022, from <https://medicalaffairs.org/real-world-evidence-regulatory-decision-making/>
- Dreyer, N. A., Hall, M., & Christian, J. B. (2020). Modernizing Regulatory Evidence with Trials and Real-World Studies. *Therapeutic Innovation & Regulatory Science*, 5(5), 1112–1115. <https://doi.org/10.1007/s43441-020-00131-5>
- Eskola, S. M., Leufkens, H. G. M., Bate, A., De Bruin, M. L., & Gardarsdottir, H. (2022). Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018–2019. *Clinical Pharmacology & Therapeutics*, 111(1), 310–320. <https://doi.org/10.1002/cpt.2462>
- Evgenia Alekseevna. (2022). *PHARMACOEPIDEMIOLOGICAL AND CLINICAL AND ECONOMIC EVALUATION OF PSORIASIS THERAPY IN REAL PRACTICE IN THE RUSSIAN FEDERATION* [Federal State Autonomous Educational Institution higher education “Peoples’ Friendship University of Russia”]. https://www.volgmed.ru/uploads/dsovet/thesis/2-993-novoderezhkina_evgeniya_alekseevna.pdf
- Lynch, H. F., & Bateman-House, A. (2020). Facilitating Both Evidence and Access: Improving FDA’s Accelerated Approval and Expanded Access Pathways. *Journal of Law, Medicine & Ethics*, 48(2), 365–372. <https://doi.org/10.1177/1073110520935352>
- Mack, C. D., Pavesio, A., Kelly, K., Irwin, D. E., Maislin, G., Jones, J., Wester, T., & Zura, R. (2021). Breaking Barriers: Studying Fracture Healing in the BONES Program. *Journal*

- of Orthopaedic Trauma*, 35, S22. <https://doi.org/10.1097/BOT.0000000000002035>
- Mahendraratnam, N., Mercon, K., Gill, M., Benzing, L., & McClellan, M. B. (2022). Understanding Use of Real-World Data and Real-World Evidence to Support Regulatory Decisions on Medical Product Effectiveness. *Clinical Pharmacology & Therapeutics*, 111(1), 150–154. <https://doi.org/10.1002/cpt.2272>
- Nirosha Mahendraratnam, Kerra Mercon, Joy Eckert, Morgan Romine, Adam Kroetsch, Katherine Frank, Rachel Sherman, Gregory Daniel, & Mark McClellan. (2019). *Adding Real-World Evidence to a Totality of Evidence Approach for Evaluating Marketed Product Effectiveness*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/adding-real-world-evidence-totality-evidence-approach-evaluating-marketed-product>
- Novoderezhkina, E. A., Алексеевна, Н. Е., Zyryanov, S. K., & Кенсаринович, З. С. (2021). THE ROLE OF REAL CLINICAL PRACTICE DATA IN MODERN HEALTHCARE. *Farmaciya (Pharmacy)*, 70(3), Article 3. <https://doi.org/10.29296/25419218-2021-03-01>
- Sarri, G., Patorno, E., Yuan, H., Guo, J. (Jeff), Bennett, D., Wen, X., Zullo, A. R., Largent, J., Panaccio, M., Gokhale, M., Moga, D. C., Ali, M. S., & Debray, T. P. A. (2022). Framework for the synthesis of non-randomised studies and randomised controlled trials: A guidance on conducting a systematic review and meta-analysis for healthcare decision making. *BMJ Evidence-Based Medicine*, 27(2), 109–119. <https://doi.org/10.1136/bmjebm-2020-111493>

A Roadmap for Developing Study Endpoints in Real-World Settings

“The RWE Endpoints Paper”

- Cottu, P., Ramsey, S. D., Solà-Morales, O., Spears, P. A., & Taylor, L. (2022). The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making. *The Breast*, *61*, 118–122. <https://doi.org/10.1016/j.breast.2021.12.015>
- He, W., Fang, Y., Wang, H., & Chan, I. (2021). Applying Quantitative Approaches in the Use of RWE in Clinical Development and Life-Cycle Management. *Statistics in Biopharmaceutical Research*, *0*(0), 1–12. <https://doi.org/10.1080/19466315.2021.1927827>
- Jaksa, A., Bloudek, L., Carlson, J. J., Shah, K., Chen, Y., Patrick, A. R., McKenna, A., & Campbell, J. D. (2022). Key learnings from Institute for Clinical and Economic Review's real-world evidence reassessment pilot. *International Journal of Technology Assessment in Health Care*, *38*(1), e32. <https://doi.org/10.1017/S0266462322000162>
- Jaksa, A., & Mahendraratnam, N. (2021). Learning from the past to advance tomorrow's real-world evidence: What demonstration projects have to teach us. *Journal of Comparative Effectiveness Research*, *10*(16), 1169–1173. <https://doi.org/10.2217/ce-2021-0166>
- Kerra Mercon, Nirosha Mahendraratnam, Joy Eckert, Christina Silcox, Morgan Romine, Kathryn Lallinger, Adam Kroetsch, Huzyfa Fazili, Marta Wosinska, & Mark McClellan. (2020). *A Roadmap for Developing Study Endpoints in Real-World Settings*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/roadmap-developing-study-endpoints-real-world-settings>
- Rivera, D. R., Henk, H. J., Garrett-Mayer, E., Christian, J. B., Belli, A. J., Bruinooge, S. S., Espirito, J. L., Sweetnam, C., Izano, M. A., Natanzon, Y., Robert, N. J., Walker, M. S., Cohen, A. B., Boyd, M., Enewold, L., Hansen, E., Honnold, R., Kushi, L., Mishra Kalyani, P. S., ... Allen, J. D. (2022). The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies. *Clinical Pharmacology & Therapeutics*, *111*(1), 283–292. <https://doi.org/10.1002/cpt.2453>
- Stern, A. D., Brönneke, J., Debatin, J. F., Hagen, J., Matthies, H., Patel, S., Clay, I., Eskofier, B., Herr, A., Hoeller, K., Jaksa, A., Kramer, D. B., Kyhlstedt, M., Lofgren, K. T., Mahendraratnam, N., Muehlan, H., Reif, S., Riedemann, L., & Goldsack, J. C. (2022). Advancing digital health applications: Priorities for innovation in real-world evidence generation. *The Lancet Digital Health*, *4*(3), e200–e206. [https://doi.org/10.1016/S2589-7500\(21\)00292-2](https://doi.org/10.1016/S2589-7500(21)00292-2)

Point-of-Care Clinical Trials: Integrating Research and Care Delivery

“The POC Paper”

- No Citations as of December 2022 according to Google Scholar

Aligning Shared Evidentiary Needs Among Payers and Regulators for a Real-World Evidence Ecosystem

“The SEO Paper”

- No Citations as of December 2022 according to Google Scholar